Tommaso Stroffolini1, Evangelista Sagnelli2, Caterina Sagnelli2, Maurizio Russello3, Massimo De Luca4, Floriano Rosina5, Bruno Cacopardo6, Giuseppina Brancaccio7, Caterina Furlan1, Giovanni Battista Gaeta7, Anna Licata8, Piero Luigi Almasio9. 1. Department of Tropical and Infectious Diseases, Policlinico Umberto Primo, Rome, Italy. 2. Department of Mental Health and Public Medicine, Second University of Naples, Caserta, Italy. 3. Operative Unit of Hepatology and Gastroenterology, A.R.N.A.S. Garibaldi-Nesima of the Catania, Catania, Italy. 4. Liver Unit, Division of Hepatology, Department of Transplantation, Cardarelli Hospital, Naples, Italy. 5. Hepatogastroenterology Division, Ospedale Gradenigo, 10153, Turin, Italy. 6. Department of Clinical and Experimental Medicine, Institute of Infectious Diseases, University of Catania, Catania, Italy. 7. Infectious Diseases, Department of Mental and Physical Health and Preventive Medicine, Second University of Naples, Naples, Italy. 8. Gastroenterology and Hepatology Unit, Biomedical Department of Internal and Specialized Medicine (Di.Bi.M.I.S.), University of Palermo, Piazza delle Cliniche, 2, 90127, Palermo, Italy. 9. Gastroenterology and Hepatology Unit, Biomedical Department of Internal and Specialized Medicine (Di.Bi.M.I.S.), University of Palermo, Piazza delle Cliniche, 2, 90127, Palermo, Italy. piero.almasio@unipa.it.
Abstract
BACKGROUND: The endemicity of hepatitis delta virus infection in Italy has decreased in the last decades. AIM: To evaluate the current epidemiology of chronic delta infection in Italy and to compare the present findings with the corresponding figures from the previous studies. METHODS: A cross-sectional study involving 16 referral centres scattered all over the country in 2014. RESULTS: Out of the 513 hepatitis B surface antigen-positive subjects enrolled, 61 (11.9%) were anti-delta positive, with a sex ratio (M/F) of 2.05. The majority (80.3%) of them was 50 years or older, while the proportion of subjects younger than 30 years of age was as low as 3.3%. No difference was detected by geographical area of residence. The presence of liver cirrhosis was diagnosed in 52.4% of cases. In comparison to previous studies, a further shift towards the oldest age groups and an increasing proportion of subjects having liver cirrhosis among all anti-delta-positive subjects are observed. CONCLUSIONS: Currently, hepatitis delta infection mostly affects old people who have an advanced but indolent liver disease, reflecting a survival effect. The defective hepatitis delta virus is near to disappear in the country, where it has been discovered in the second half of 70s.
BACKGROUND: The endemicity of hepatitis delta virus infection in Italy has decreased in the last decades. AIM: To evaluate the current epidemiology of chronic delta infection in Italy and to compare the present findings with the corresponding figures from the previous studies. METHODS: A cross-sectional study involving 16 referral centres scattered all over the country in 2014. RESULTS: Out of the 513 hepatitis B surface antigen-positive subjects enrolled, 61 (11.9%) were anti-delta positive, with a sex ratio (M/F) of 2.05. The majority (80.3%) of them was 50 years or older, while the proportion of subjects younger than 30 years of age was as low as 3.3%. No difference was detected by geographical area of residence. The presence of liver cirrhosis was diagnosed in 52.4% of cases. In comparison to previous studies, a further shift towards the oldest age groups and an increasing proportion of subjects having liver cirrhosis among all anti-delta-positive subjects are observed. CONCLUSIONS: Currently, hepatitis delta infection mostly affects old people who have an advanced but indolent liver disease, reflecting a survival effect. The defective hepatitis delta virus is near to disappear in the country, where it has been discovered in the second half of 70s.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: T Stroffolini; L Ferrigno; L Cialdea; R Catapano; F Palumbo; F Novaco; A Moiraghi; C Galanti; R Bernacchia; A Mele Journal: J Hepatol Date: 1994-12 Impact factor: 25.083
Authors: S Gaiani; L Gramantieri; N Venturoli; F Piscaglia; S Siringo; A D'Errico; G Zironi; W Grigioni; L Bolondi Journal: J Hepatol Date: 1997-12 Impact factor: 25.083
Authors: F Rosina; P Conoscitore; R Cuppone; G Rocca; A Giuliani; R Cozzolongo; G Niro; A Smedile; G Saracco; A Andriulli; O G Manghisi; M Rizzetto Journal: Gastroenterology Date: 1999-07 Impact factor: 22.682
Authors: A Smedile; C Lavarini; P Farci; S Aricò; G Marinucci; P Dentico; G Giuliani; A Cargnel; C Del Vecchio Blanco; M Rizzetto Journal: Am J Epidemiol Date: 1983-02 Impact factor: 4.897
Authors: Mathias Jachs; Teresa Binter; Caroline Schmidbauer; Lukas Hartl; Michael Strasser; Hermann Laferl; Stephanie Hametner-Schreil; Alexander Lindorfer; Kristina Dax; Rudolf E Stauber; Harald H Kessler; Sebastian Bernhofer; Andreas Maieron; Lorin Loacker; Simona Bota; Isabel Santonja; Petra Munda; Mattias Mandorfer; Markus Peck-Radosavljevic; Heidemarie Holzmann; Michael Gschwantler; Heinz Zoller; Peter Ferenci; Thomas Reiberger Journal: United European Gastroenterol J Date: 2021-12-07 Impact factor: 4.623
Authors: Carla Usai; Upkar S Gill; Anna C Riddell; Tarik Asselah; Patrick T Kennedy Journal: Aliment Pharmacol Ther Date: 2022-03-16 Impact factor: 9.524
Authors: Gian Paolo Caviglia; Silvia Martini; Alessia Ciancio; Grazia Anna Niro; Antonella Olivero; Rossana Fontana; Francesco Tandoi; Chiara Rosso; Renato Romagnoli; Giorgio Maria Saracco; Antonina Smedile; Mario Rizzetto Journal: J Adv Res Date: 2021-03-02 Impact factor: 10.479